CAR T-Cell Therapy for NHL Market to Grow Annually by 7% Through 2036
The market for CAR T-cell therapy for non-Hodgkin lymphoma (NHL) is projected to experience robust growth, with an estimated annual increase of approximately 7% through 2036. This expansion is driven by increasing clinical adoption and the broadening of treatment indications.
The CAR T-cell therapy market for non-Hodgkin lymphoma (NHL) is expected to grow at a compound annual growth rate of around 7% through 2036, according to a market insights report by DelveInsight. The market was valued at an estimated USD 3.2 billion in 2025 across seven major markets, with the United States representing the largest share.
Growth is primarily fueled by the shift from conventional chemo-immunotherapies to advanced cell-based treatments. Factors contributing to this trend include the strong efficacy observed in relapsed and refractory (R/R) disease, increasing adoption in second-line and later treatments, and the anticipated launch of new therapies.
In 2025, the United States accounted for approximately 59% of the total market size among the leading markets, which also include Germany, France, Italy, Spain, the United Kingdom, and Japan. The total number of incident cases for selected NHL indications eligible for CAR T-cell therapy was around 159,000 in 2025 and is expected to rise during the forecast period extending to 2036.
Key companies, such as Miltenyi Biomedicine, Novartis, and Wugen, are developing novel CAR T-cell therapies. Promising treatments currently in clinical trials are expected to further expand market opportunities in the coming years.